The Food and Drug Administration on Thursday approved the Alzheimer’s treatment Leqembi, a pivotal decision that is expected to expand access to the expensive drug for older Americans.…
Read more FDA approves Alzheimer’s drug Leqembi, paving way for broader Medicare coverageThe U.S. Food and Drug Administration on Thursday granted full approval to the Biogen BIIB and Eisai Co. Ltd. ESALF Alzheimer’s treatment Leqembi, a step that secures Medicare…
Read more FDA approves Alzheimer’s treatment Leqembi, clearing the way for Medicare coverageJuanmonino | E+ | Getty Images Seniors with early Alzheimer’s disease will face major hurdles to get treated even if promising new drugs roll out more broadly in…
Read more Alzheimer’s patients may wait years to get treated with new drugs, putting them at risk of more severe diseaseMedicare will not provide broader coverage of the Alzheimer’s drug Leqembi until it receives more evidence that the treatment is reasonable and necessary, according to the federal agency…
Read more Medicare rejects Alzheimer’s Association request for unrestricted coverage of treatments like LeqembiCheck out the companies making headlines before the bell: Tesla (TSLA) – Tesla CEO Elon Musk said he would refrain from selling any more Tesla stock for 18…
Read more Stocks making the biggest moves premarket: Tesla, Nutanix, Meta and more
